Emerging antibody products and Nicotiana manufacturing

Hum Vaccin. 2011 Mar;7(3):349-56. doi: 10.4161/hv.7.3.14266. Epub 2011 Mar 1.

Abstract

Antibody based products are not widely available to address multiple global health challenges due to high costs, limited manufacturing capacity, and long manufacturing lead times. Nicotiana-based manufacturing of antibody products may now begin to address these challenges as a result of revolutionary advances in transient expression and altered glycosylation pathways. This review provides examples of emerging antibody-based products (mucosal and systemic) that could be competitive and commercially viable when the attributes of Nicotiana-based manufacturing (large scale, versatile, rapid, low cost) are utilized.

Publication types

  • Research Support, N.I.H., Extramural
  • Review

MeSH terms

  • Alzheimer Disease / immunology
  • Amyloid beta-Peptides / immunology
  • Animals
  • Antibodies, Monoclonal / biosynthesis*
  • Antibody Formation*
  • Autoimmune Diseases / drug therapy
  • Biological Products / biosynthesis
  • Biological Warfare / prevention & control
  • Commerce
  • Communicable Diseases, Emerging / immunology
  • Communicable Diseases, Emerging / prevention & control
  • Contraception / methods
  • Glycosylation
  • Humans
  • Immunoglobulin G / therapeutic use
  • Immunoglobulins, Intravenous / therapeutic use
  • Inflammation / drug therapy
  • Mice
  • Polysaccharides / biosynthesis
  • Pregnancy, Unplanned
  • Respiratory Syncytial Virus Infections / economics
  • Respiratory Syncytial Virus Infections / prevention & control
  • Respiratory Syncytial Viruses / immunology
  • Sexually Transmitted Diseases / prevention & control
  • Tobacco / immunology
  • Tobacco / metabolism*
  • Vaccines, Subunit / biosynthesis

Substances

  • Amyloid beta-Peptides
  • Antibodies, Monoclonal
  • Biological Products
  • Immunoglobulin G
  • Immunoglobulins, Intravenous
  • Polysaccharides
  • Vaccines, Subunit